[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Yu GP, Wang SJ, Shi J, Zhao YQ: [Clinical features and prognosis in 49 patients with Castleman's disease]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):570-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis in 49 patients with Castleman's disease].
  • OBJECTIVE: To analyze the clinical features and prognosis of patients with Castleman's disease (CD).
  • RESULTS: In patients with uni-centric CD (UCD), hyaline vascular type had the highest percentage (88.2%, 15/17), which was significantly higher than that of either plasma cell type (5.9%, 1/17) or mixed cell type (5.9%, 1/17) (P < 0.05).
  • Twenty-three out of 29 patients with MCD were treated with chemotherapy; only 6 patients achieved CR and 9 achieved partial remission (PR), and the overall response rate was 65.2%.
  • New drugs and clinical trials are needed to improve the outcome of MCD.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / therapy

  • Genetic Alliance. consumer health - Castleman's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968073.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Chen CH, Liu HC, Hung TT, Liu TP: Possible roles of Epstein-Barr virus in Castleman disease. J Cardiothorac Surg; 2009;4:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible roles of Epstein-Barr virus in Castleman disease.
  • BACKGROUND: Complete resection seemed to be curative in patients with Castleman disease of any location but the disease is likely to be reactive in its pathogenesis.
  • The relation between Epstein-Barr virus and Castleman disease has not been elucidated.
  • We tried to define the role of Epstein-Barr virus in the pathogenesis of Castleman disease.
  • METHODS: 20 cases of Castleman disease were retrospectively reviewed from 1993 to 2006.
  • At least 2 to 4 representative sections of formalin-fixed, paraffin-embedded specimens from each patient were obtained to examine the presence of EBV and its localization by hematoxylin-eosin stain, immunohistochemistry, polymerase chain reaction and In-situ hybridization RESULTS: Hyaline-vascular type was diagnosed in 18 cases, plasma cell type in 1 and mixed type in 1 case.
  • CONCLUSION: There is a strong association between Castleman disease and Epstein-Barr virus.
  • EBV may have a potential role in angiogenesis of Castleman disease.
  • For smaller lesion with high activity of angiogenesis but not amenable for curative resection, anti-angiogenesis medications may have a potential role to control the disease.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Giant Lymph Node Hyperplasia / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1985 Dec 20;230(4732):1350-4 [2999980.001]
  • [Cites] J Pathol. 1984 Oct;144(2):131-47 [6092594.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4253-61 [6272971.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Feb;78(2):805-9 [6262773.001]
  • [Cites] Cancer. 1972 Mar;29(3):670-83 [4551306.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1946-51 [11448908.001]
  • [Cites] Am J Pathol. 1987 Oct;129(1):86-91 [2821817.001]
  • [Cites] ANZ J Surg. 2007 May;77(5):339-43 [17497971.001]
  • [Cites] Cancer. 1956 Jul-Aug;9(4):822-30 [13356266.001]
  • [Cites] Hematol Pathol. 1995;9(1):17-26 [7628995.001]
  • [Cites] J Virol Methods. 1993 Jul;43(2):233-46 [8396156.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3372-81 [8389616.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2923-30 [1954381.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] J Clin Invest. 1990 Aug;86(2):592-9 [2384605.001]
  • [Cites] Immunology. 1990 May;70(1):100-5 [2162322.001]
  • [Cites] Blood. 1989 Sep;74(4):1360-7 [2788466.001]
  • [Cites] Am J Clin Pathol. 1989 Jan;91(1):1-5 [2535912.001]
  • (PMID = 19589162.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2715400
  •  go-up   go-down


3. Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N: Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract; 2005;201(4):325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases.
  • Several lymphoproliferative disorders may be interpreted as multicentric Castleman's disease (MCD) clinicopathologically.
  • These include HIV infection, autoimmune-disease-associated lymphadenopathy, idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia, "idiopathic MCD", POEMS syndrome (polyneuropathy, anasarca, organomegaly, endocrinopathy, M-proteins, and skin lesions), and non-Hodgkin's lymphomas.
  • We report on the clinicopathologic and immunohistologic findings of five cases of idiopathic MCD and discuss the problems regarding their differential diagnosis.
  • However, during the course of disease, minimal diagnostic criteria for POEMS syndrome, i.e., monoclonal plasma cell proliferation and sensory motor neuropathys, were absent in all five cases.
  • The serum interleukin-6 level and the vascular endothelial growth factor level were found to be elevated in two of the cases examined.
  • However, none of them fulfilled the diagnostic criteria for any of the definite autoimmune-disease.
  • Histologically, three lesions exhibited a mixed type of Castleman's disease, and two exhibited the hyaline-vascular type.
  • The majority of the germinal centers were of the hyaline-vascular or epithelioid germinal type, with a few hyperplastic germinal centers.
  • Moderate to large sheets of plasma cells were observed in three mixed type cases.
  • Few CD57-positive T-cells were observed in the hyaline-vascular and epithelioid follicles.
  • [MeSH-major] Germinal Center / pathology. Giant Lymph Node Hyperplasia / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Biomarkers / metabolism. Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Hyperplasia. Immunoenzyme Techniques. Male. Middle Aged. POEMS Syndrome / diagnosis. Treatment Outcome


Advertisement
4. McClain KL, Natkunam Y, Swerdlow SH: Atypical cellular disorders. Hematology Am Soc Hematol Educ Program; 2004;:283-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • What are the similarities and the differences between Langerhans cell histiocytosis (LCH), sinus histiocytosis with massive lymphadenopathy (SHML) or Rosai-Dorfman disease, and Castleman's disease (CD)?
  • Advocates of the malignant proliferation theory rest their case primarily on the following two points: Clonality of the CD1a+ Langerhans cells was demonstrated by analysis of the human androgen receptor in patients with single bone lesions (Low Risk) or multisystem disease including spleen, liver, bone marrow, or lung (High Risk).
  • An intriguing finding of human herpesvirus (HHV)-6 viral proteins in SHML has been reported in several patients, but needs further study.
  • Localized cases are divided into the hyaline vascular type and plasma cell type.
  • Interleukin (IL)-6 expression is increased in the plasma cell type.
  • Multicentric CD of the plasmablastic type is most often found in HIV-positive patients with coincident HHV-8 infection.
  • Other cases of multicentric CD are also most like the plasma cell type, however, with disseminated disease and constitutional symptoms.
  • A wide variety of anti-neoplastic drugs, radiation therapy, anti-IL-6 and rituximab or atlizumab have been used with varying success in patients with multicentric CD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561688.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


5. Westphal FL, Lima LC, Santana LC, Netto JC, Amaral VC, Silva Mdos S: Castleman's disease associated with follicular dendritic cell sarcoma and myasthenia gravis. J Bras Pneumol; 2010 Nov-Dec;36(6):819-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Castleman's disease associated with follicular dendritic cell sarcoma and myasthenia gravis.
  • Castleman's disease is an atypical lymphoproliferative disorder of unknown etiology, which might be associated with various clinical conditions, including autoimmune diseases and malignant neoplasms.
  • After the resection of the mediastinal tumor, the histopathological examination revealed hyaline vascular-type Castleman's disease, complicated by follicular dendritic cell sarcoma.
  • At this writing, the patient was being treated with an anticholinesterase agent and corticosteroids for the control of myasthenia gravis.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / complications. Giant Lymph Node Hyperplasia / complications. Myasthenia Gravis / diagnosis

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225186.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


6. Colleoni GW, Duarte LC, Kerbauy FR, Lobão M, Yunis MP, Alves AC, de Souza VA, Bordin JO, de Oliveira JS: 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol; 2003;42(7):784-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma.
  • There is currently no consensus on the best treatment for unresectable hyaline-vascular variant or for multicentric Castleman's disease (MCD), because none of the reported regimens have consistently produced complete response or durable remission in the majority of patients In the present study, we report on the use of 2-CdA (2-chloro-deoxyadenosine) in three patients, two of them with MCD and one with unresectable hyaline-vascular type disease.
  • 2-CdA typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.
  • 1) 2-CdA can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease;.
  • [MeSH-major] Cladribine / adverse effects. Cladribine / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Lymphoma, Non-Hodgkin / chemically induced

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14690166.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 47M74X9YT5 / Cladribine
  •  go-up   go-down


7. Al Otaibi T, Al Sagheir A, Ludwin D, Meyer R: Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report. Transplant Proc; 2007 May;39(4):1276-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post renal transplant Castleman's disease resolved after graft nephrectomy: a case report.
  • Angiofollicular lymphoid hyperplasia (Castleman's disease) is a lymphoproliferative process thought to be mediated by overexpression of II interleukin-6.
  • Castleman's disease has two variants: Castleman's disease has two variants: Hyaline vascular type and plasma cell variant (multicentric Castleman's disease).
  • The hyaline vascular type tends to be localized, and the plasma cell variant shows more systematic signs and carriers a worse clinical prognosis.
  • Castleman's disease is associated with B-cell lymphoma, Kaposi sarcoma, Human herpes virus 8 (HHV-8), and Epstein-Barr virus.
  • Castleman's disease have been described thrice post kidney transplant.
  • In this report, we document the course of a renal recipient who developed the plasma cell variant of Castleman's disease at 16 months after failure of his allograft and return to dialysis.
  • To our knowledge, this is the first case where the disease manifestations disappeared after graft removal.
  • Our patient experienced chronic renal allograft rejection which may have driven all the systematic manifestations of multicentric castleman's disease and possibly reactivated a latent HHV-8 infection.
  • In this case immunohistochemical testing for HHV-8 was not available to prove a role for this agent.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Kidney Transplantation / adverse effects
  • [MeSH-minor] Humans. Immunosuppressive Agents / therapeutic use. Lymph Nodes / pathology. Male. Middle Aged. Nephrectomy. Renal Dialysis. Reoperation






Advertisement